Respiratory Syncytial Virus: Vaccination

Department of Health and Social Care written question – answered at on 5 April 2024.

Alert me about debates like this

Photo of Baroness Ritchie of Downpatrick Baroness Ritchie of Downpatrick Non-affiliated

To ask His Majesty's Government how they plan to assess the wider productivity and economic benefits of any new immunisation programmes for infant respiratory syncytial virus.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

The independent Joint Committee for Vaccination and Immunisation (JCVI) advises the Department on the approach to vaccination and immunisation. The JCVI’s evaluation of the cost-effectiveness of a respiratory syncytial virus (RSV) programme was based on the health benefits of an infant RSV programme, and the potential healthcare cost savings from preventing cases and hospitalisations.

The Department did not ask the JCVI to complete an assessment of the wider productivity and economic benefits when determining the cost-effectiveness of a vaccination programme, and the Department did not assess this separately for RSV.

Does this answer the above question?

Yes1 person thinks so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.